Update on the challenges and recent advances in cancer immunotherapy

Gianfranco Baronzio1
Gurdev Parmar2
Irina ZH Shubina3
Valter Cassutti1
Sergio Giuli1
Marco Ballerini1
Mikhail Kiselevsky3

1Centro Medico Demetra: Hyperthermia and Immunity Center, Terni, Italy; 2Integrated Health Clinic, Fort Langley, British Columbia, Canada; 3Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia

Correspondence: Gianfranco Baronzio
Centro Medico Demetra: Hyperthermia and Immunity Center, via Cassian Bon, I/A 05100 Terni, Italy
Tel +39 331 877 872
Email barongf@intercom.it

Abstract: This overview provides an analysis of some of the immunotherapies currently in use and under investigation, with a special focus on the tumor microenvironment, which we believe is a major factor responsible for the general failure of immunotherapy to date. It is our expectation that combining immunotherapy with methods of altering the tumor microenvironment and targeting regulatory T cells and myeloid cells will yield favorable results.

Keywords: tumor microenvironment, tumor immunity, immunosuppression, CTLA-4, PD-1, exosomes, myeloid-derived suppressor cells, Tregs

Introduction
Metastasis occurs in the late stages of cancer development and partly represents the failure of both the innate and adaptive immune systems.1 Several factors support this process; among these, angiogenesis and chronic peritumoral inflammation may be two of the most important.1–3 There are also clinical factors that must be considered and may be of equal importance, such as tumor volume,4 prior treatment history, and the quality and quantity of that treatment,5,6 the struggle for nutrients,7 and the presence or absence of neurotransmitters.8 Despite this complexity, a clearer vision of the interactions between tumor and stroma/environment is possible, and its importance alongside immunotherapy is becoming more and more evident.9,10

Further, with the advent of new drugs (eg, ipilimumab), there has been a renewed clinical interest in cancer immunotherapy. Results from some of these newer immunologic drugs have suggested that active immunotherapy represents an important pathway to eliminating residual disease and obtaining durable and long-lasting responses in cancer patients.10,11

Within the tumor area, several cells are present at the same time. While some of these cells are normal residents, such as fibroblasts and cells of the immune system (leukocytes, lymphocytes, and macrophages), others are recruited. For example, several classes of cell types are recruited to the tumor environment specifically because of the hypoxic microenvironment.11–14 Resident cells initially try to continue their homeostatic existence controlling tumor growth but are eventually substituted by more immature cells – myeloid-derived suppressor cells (MDSCs) – recruited by bone marrow.13,14 Once MDSCs arrive into the tumor area, they are quickly differentiated into cells such as type 2 macrophages (M2s)14 or N2-type neutrophils,15 which are able to sustain this environment of angiogenesis and chronic inflammation.19 Ultimately, this results in the creation of an increasingly immunosuppressive environment,16 with the invasion...
The next part of this article briefly describes some aspects of adoptive immunotherapy and the modification of aspects of the tumor microenvironment, particularly $T_{reg}$, exosomes, and MDSCs.

Adoptive immunotherapy

NKs

NK cells were discovered in humans and mice in 1975, with specific functional criteria that correspond to their ability to lyse certain tumor cells in the absence of prior stimulation. NK cells are large granular lymphocytes that belong to the innate immune system. Unlike T or B lymphocytes of adaptive or antigen-specific immunity, NK cells do not rearrange T-cell receptor (TCR) or immunoglobulin genes from their germ-line configuration. Morphologically, NK cells are large granular lymphocytes that show (due to a large number of secreting granules) high functional activity. NK cells make up only 5%–20% of the total number of lymphocytes, including those that express cluster of differentiation (CD) 16 and CD56 surface markers. NK cells are able to detect and lyse cells despite deficiency in the expression of major histocompatibility complex (MHC) class I molecules, improving our understanding of the function and the role of NK cells in the immune response.

NK cells have IL-2 receptors and can evidently be activated by this endogenous cytokine or its exogenous analogs. NK cells are thus effectors of innate immunity and, unlike T-killer cells, their function does not require a cascade of antigen-presentation reactions.

As with neutrophils, NK cells may be considered the first line of defense of immune surveillance, as they can cause lysis of a transformed cell after contacting it, without any additional stimuli. However, their triggering function relies on a complex balance between inhibitory and activating signals that requires not only deficient MHC class I expression on target cells but also the expression of inducible ligands of activating NK-cell receptors. Both of these points are crucial for antitumor immunity performance, since, in the course of transformation, tumor cells may shed MHC molecules, lose tissue-specific antigens, and, what is more, can acquire features of embryonic cells (low-differentiated embryo carcinomas), thereby “escaping” specific immunity. However, these particular malignant cells may become the target for NKs, which have the ability to recognize and destroy a wide range of abnormal cells (including tumor, virus-infected, antibody-bound, and allogeneic cells) and stressed cells without damaging healthy and normal “self” cells.
LAK generation

IL-2 stimulation of lymphocytes leads to expression of the so-called LAK cells. LAKs are a heterogeneous population of cells consisting primarily of NK, NKT, and T cells, which are generated in vitro by culture of peripheral blood mononuclear cells in the presence of IL-2. The major effector subset in the LAK population is of NK cells, which are mechanistically equivalent to peripheral blood NK cells but are more cytotoxic against tumor cells, including NK-resistant targets.38-41

Adoptive IL-2/LAK therapy of cancer

The first true clinical progress in immunotherapy was seen after the introduction of recombinant DNA technology for the production of immune-stimulating cytokines. Since 1985, studies on combined IL-2 and LAK cell treatment have been published.23,24 Such clinical trials have shown that high-dose IL-2 alone or in combination with LAK cells mediates objective tumor regression in 17%–28% of patients with metastatic renal cancer or metastatic melanoma, while prolonged remission was even observed in some patients with metastatic cancers.23,24,40

Some authors have reported on clinical trials of the systemic treatment with high-dose IL-2 and tumor-infiltrating lymphocytes (autologous lymphocytes can be isolated from tumor-infiltrating cells, which presumably express tumor-specific TCRs) of patients with advanced cancer. Such treatment resulted in a 34% objective response rate of patients with metastatic melanoma.40 Although there was considerable clinical interest in LAKs for antitumor therapy by the end of the last century, LAK therapy has failed to obtain public support as a standard therapy for cancer patients. This was largely the result of limited responses to the immunotherapy when compared with those to chemotherapy or radiation therapy, and there were concerns about toxicity associated with the IL-2 infused simultaneously in order to maintain LAK activation.

Another confounding factor was that most studies on immunotherapy used terminal-stage patients with virtually no remaining immune response capabilities, as they had failed to respond to previous conventional treatments.41

More recently, a new, cell-based immunotherapy utilizing activated lymphocytes has been suggested as an adjuvant regimen to radical surgery of cancer patients. Kimura and Yamaguchi42 conducted a randomized trial of 174 patients with non-small-cell lung carcinoma comparing IL-2/LAK therapy in combination with chemotherapy versus chemotherapy alone. Patients had undergone curative resection of their lung carcinoma and received six to eight courses of IL-2/LAK therapy over 2 years. The authors reported an improvement in the 5- and 9-year survival rates of 21% and 28%, respectively.

Adjuvant treatment of solid tumors has also involved cytokine-induced killers (CIKs). CIK cells are a heterogeneous subset of ex vivo expanded T lymphocytes presenting a mixed T-NK phenotype and have unrestricted MHC antitumor activity.41 In the setting of hepatocellular carcinoma and gastric cancers, adjuvant infusions of autologous CIK cells after surgical resection resulted in a significant increase in disease-free survival.44-46 To increase IL-2/LAK immunotherapy effectiveness, local and loco-regional infusions were performed, allowing for the effective concentration of activated killers at the site of the lesion. The most significant clinical effects were achieved with intra-cavity infusions of IL-2 and LAKs in patients with malignant effusions (pleuritis, ascites, and pericarditis).

Malignant effusion regression was seen in 70%–95% of cases, showing good tolerance and effectiveness in chemotherapy-resistant cancer types.47 One of the advantages of adjuvant loco-regional immunotherapy is that these low IL-2 immunostimulating doses cause no marked side effects, including immune- and/or myelosuppression, which are characteristic of high-dose cytokine therapy.

These LAK- and CIK-cell immunotherapy methods aim to stimulate the innate chain of antitumor immunity, which is a reasonable approach because most tumors express little to no MHC or tumor antigens. It is also necessary to consider the fact that T killers constitute an essential part of lymphoid cell populations and are responsible for a more specific mechanism of action – in these conditions, they are not involved in the antitumor defense function. Therefore, another promising approach in antitumor biotreatment is focusing on designing vaccines, in particular DC-based vaccines, to activate adaptive immunotherapy.

Tumor-infiltrating lymphocytes (TILs) in cancer immunotherapy

TILs derived from patients with a variety of histological cancer types have demonstrated that cellular immune reactions against established malignancies exist in humans. TILs are heterogeneous populations of T cells, which contain not only CD4+ and CD8+ T lymphocytes (as previously reported),30,38,48 but also a small and, in some cases, significant fraction of γδ T cells, with a prevalence of the Vδ1 subset.48,49
TILs that infiltrate melanoma could specifically recognize tumor-associated antigens.\textsuperscript{30} Chemotherapy-induced lymphodepletion prior to adoptive cell infusion may lead to the dramatic enhancement of the persistence of the transferred cells and improved anticancer effects.\textsuperscript{30} Early results in patients with metastatic melanoma treated with the adoptive transfer of autologous TILs selected for antitumor activity – expanded in vitro and then re-infused into patients along with IL-2, following a lymphodepleting preparative regimen – do exist.\textsuperscript{30} In clinical trials with increasing lymphodepletion prior to infusion of autologous TILs, objective response rates between 49\% and 72\% were seen for patients with metastatic melanoma.\textsuperscript{30}

Limitations of TIL therapy, including the requirement for surgery to isolate the tumor and the need to consistently generate T cells with antitumor activity, have led to novel strategies for redirecting normal T cells to recognize tumor-associated antigens (eg, NY-ESO-1, carcinoembryonic antigen [CEA], anti-CD20) using genetically engineered tumor antigen-specific TCRs or chimeric antigen receptor genes. As an alternative to TIL therapy, highly avid TCRs can be cloned from naturally occurring T cells, and then gene transfer vectors can be used to introduce these into the patient’s lymphocytes. In this manner, large numbers of antigen-specific T cells can be rapidly generated, in comparison with the long-term expansion required for TILs. These highly reactive T-cell clones are able to recognize and effectively lyse target tumor cells.\textsuperscript{30,48}

Recently, several clinical trials have reported the clinical efficacy and benefit of gene-modified T cells for the treatment of different cancers, including melanoma, colorectal and synovial cell cancers, neuroblastoma, and lymphoma. In patients with synovial cell cancer, the measurable response rate was 66\%, while in melanoma patients this was 45\%.\textsuperscript{57,50}

### Autologic vaccines based on DCs

DCs are the quintessential antigen-presenting cells (APC) and have the unique ability to induce a primary immune response. DCs both prime naive cytotoxic T cells and activate long-term memory cells. In addition to these essential functions in adaptive immunity, DCs can also activate B cells and NKs.\textsuperscript{51}

### Methods of DC generation to produce antitumor vaccines

Mature DCs for antitumor vaccines are typically generated from CD14+ monocytes according to a well-known two-stage method. The initial stage is cultivation for 6–7 days in the presence of granuloctye macrophage colony-stimulating factor and IL-4 in macrophage-conditioned medium.\textsuperscript{52}

The second stage – DC maturation – may proceed in the presence of various factors, such as bacteria (live or dead), bacterial products, lipopolysaccharide, viruses, two-strand RNA or its analog poly-I-C, pro-inflammatory factors and their combinations (IL-1\(\beta\), tumor necrosis factor-\(\alpha\), IL-6, prostaglandin E2 [PGE\(_2\)], and CD40 ligand (CD40L). Compared to mature Dendritic Cells, maturing DCs lose their ability for endocytosis and the processing of antigens.\textsuperscript{51,52}

Early studies on the use of DCs involved only small groups of patients but reported potentially promising results.\textsuperscript{53,54} Today, we have access to the results of over 200 clinical trials that have assessed DC-based vaccines, yet their clinical effectiveness and expedience for use in cancer patients becomes more and more doubtful. Rosenberg et al argued that early optimism for DC vaccines was based on dubious surrogate end-points, which lacked robustness, rather than on proof of antitumor effects.\textsuperscript{55–57} One trial, conducted at the Surgery Branch of the National Cancer Institute on 440 patients, yielded an overall objective response rate of only 2.6\%.\textsuperscript{55} This was comparable to the 4.0\% response rate reported in 40 other smaller studies on a combined total of 756 patients.\textsuperscript{57} More recent studies have shown partial or complete regression rates of 4\%–12\% in patients with advanced cancer.\textsuperscript{55,57}

When compared with IL-2/LAK therapy, the clinical effectiveness of DC-based therapy has not been reported to be more effective, and was sometimes less, than that of IL-2/LAK.\textsuperscript{55,57} These limited response rates may be due to the fact that DC-vaccine therapy results in stimulation of effector cells of innate immunity, where the antitumor effect is not specifically taught to T lymphocytes for long-lasting protection. Moreover, there are even data that suggest DC vaccination can have a detrimental effect and may even be associated with a worse outcome.\textsuperscript{57}

In recent years, there have been reports about the efficiency of a new cell-based immunotherapy for advanced prostate cancer called “sipuleucel-T.” Sipuleucel-T is an autologous active cellular immunotherapy consisting of peripheral blood mononuclear cells, including APCs. It is the first therapeutic cancer vaccine to have received US Food and Drug Administration approval. The treatment resulted in a prolonged median overall survival, but only in patients with no signs of disease progression.\textsuperscript{58–60} It is hypothesized that the activated APCs promote endogenous T cells to destroy prostatic acid phosphatase (PAP)-bearing prostate cancer cells, although the vaccine’s precise mechanism of
action is not yet understood. However, there is a lack of data about the generation of adaptive immunity using this method, suggesting that its antitumor effect is achieved mainly by activating effectors of innate immunity as a result of stimulating factors secreted by DCs; that is to say, the DCs may be considered a cellular adjuvant to NK cells and other innate immunity cells.

Overall, DC-based vaccines have not demonstrated any significant clinical efficacy and the outcomes of clinical trials have largely been poor. A more efficient approach using this method might be to use it to prolong progression-free survival in cancer patients who have had maximal cytoreduction via surgery and/or chemotherapy. DCs may also be used as a cellular adjuvant for other cancer immunotherapy strategies, in particular, in combination with LAK (CIK) therapy. Such an approach may improve the effectiveness of cell-based antitumor immunotherapy due to the simultaneous activation of both innate and adaptive immunity. Further, taking into account NK/DC interactions, such combination treatments may increase the effectiveness of LAK cells by DC stimulation and enhance the generation of CTLs in their presence.

Control of the tumor microenvironment

The tumor microenvironment is a microcosm of cells and extracellular matrices that continuously interact and evolve. The support cells (ie, fibroblasts, adipocytes), the matrix, and the immunity cells that are partly comprised of normal residents and partly of recruited cells (T\textsubscript{reg}, MDSCs, macrophages, and neutrophils) work in concert with the tumor cells to create an inflammatory microenvironment that permits their growth and metastasis. The inflammatory microenvironment is largely responsible for the failure of host immune surveillance. Further, the excessive production of lipid mediators such as PGE\textsubscript{2}, immune regulator cytokines such as IL-10, and transforming growth factor-\(\beta\) (TGF-\(\beta\)) carries through to immunosuppression. The excessive production of these lipid mediators in this already inflamed microenvironment allows for control of T\textsubscript{reg} and MDSCs creating the perfect conditions for chronic disease. The immunosuppressive activity of PGE\textsubscript{2} has long been known, and we know it is continually produced by tumor cells and by their stroma. Its excessive production can regulate T\textsubscript{reg} and MDSC recruitment. Cyclooxygenase-2 (COX2) inhibitors have been demonstrated to decrease PGE\textsubscript{2}, and thus the recruitment of T\textsubscript{reg} in mouse mammary models and lung models, and are associated with a differentiation effect on MDSCs that has been demonstrated in rare tumors such as mesothelioma.

Leibovici et al have noted that the tumor microenvironment is a target for TGF-\(\beta\) action that stimulates tumor progression via pro-tumorigenic effects on vascular, immune, and fibroblastic cells. According to these authors, there are several preclinical types of TGF-\(\beta\) inhibitors, each of which must be used prudently. Another approach to controlling the excessive production of TGF-\(\beta\) in the tumor microenvironment is the use of oral proteolytic enzymes, as demonstrated by Desser et al in patients with rheumatoid arthritis, osteomyelofibrosis, and herpes zoster. The mechanism of action of these enzymes seems to be linked to inactivation by \(\alpha\)2 macroglobulin. MDSCs are identified as CD11b\textsuperscript{+}Gr1\textsuperscript{+} in mice and CD33\textsuperscript{+}HLA–DR–Lin– in humans although numerous additional markers (eg S100A, etc) have been used to categorize MDSC subsets. MDSCs are a heterogeneous group of mature and immature myeloid cells that demonstrate strong immunosuppressive activity, due to several factors triggered by the phosphorylation of signal transducer and activator of transcription 3 (STAT3). Once STAT3 is phosphorylated, MDSCs are activated and produce various products such as PGE\textsubscript{2}, vascular endothelial growth factor, reactive oxygen species, IL-10 and IL-6, nitric oxide synthase, and low-molecular-weight cytoplasmic proteins called S100A8/9 (which is able to fix calcium). Due to their heterogeneity, MDSCs are not easily treated; nonetheless, currently, several clinical approaches are in development and trials are underway to this end. Various approaches have been used to attempt to control the recruitment, differentiation, and number – by appropriate chemotherapy of MDSCs. Recently, Ghiringhelli et al reported on a novel approach to controlling tumor immunity and inflammation via polyphenols such as resveratrol, curcumin, genistein, and epigallocatechin. This novel treatment method is of particular interest at least because the side effects are minimal, and these natural molecules act simultaneously on a number of key control points (IL-10, TGF-\(\beta\), PGE\textsubscript{2}, leukotrienes) and by increasing tumor cell death. Some of the drugs used to modulate MDSCs in humans and their mechanisms of action are presented in Table 1 and Figure 1.

Another group of cells present in the blood and the hypoxic tumor microenvironment that are able to suppress the host immune response is the T\textsubscript{reg} classified as CD4\textsuperscript{+}CD25\textsuperscript{+}FOxp3. They contribute to angiogenesis and to poor survival in many solid tumors such as ovary, breast, colorectal, lung, and pancreatic cancers. T\textsubscript{reg} can be depleted or modulated in five ways: (1) by depletion (gemcitabine,
Table 1 Clinical drugs modulating human myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) and their mechanism(s) of action

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>Cancer</th>
<th>Mechanism(s) of action</th>
<th>PMA</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin D3</td>
<td>Head and neck</td>
<td>↓ CD34 (+), ↑ CD8+ (↑) T cells</td>
<td>D</td>
<td>Lathers et al, Ugel et al</td>
</tr>
<tr>
<td>ATRA</td>
<td>Renal carcinoma</td>
<td>Induction of differentiation</td>
<td>D</td>
<td>Mirza et al, Apetoh et al</td>
</tr>
<tr>
<td>Sunitinib</td>
<td>Renal cell carcinoma</td>
<td>Prevention of MDSC generation, differentiation mediated by c-kit and transcription factor (STAT3) inhibition</td>
<td>M</td>
<td>Greten et al, Kao et al, Ko et al, Apetoh et al, Ugel et al</td>
</tr>
<tr>
<td>COX2 inhibitors</td>
<td>Mesothelioma</td>
<td>↓ recruitment of MDSCs</td>
<td>M</td>
<td>Veltman et al, Ugel et al</td>
</tr>
<tr>
<td>Bevacizumab (anti-VEGF antibody)</td>
<td>Metastatic renal, cervical, colon, mesothelioma</td>
<td>Induction of differentiation toward more mature form of MDSCs</td>
<td>M</td>
<td>Nagaraj and Gabrilovich, van Cruijsen et al, Ugel et al</td>
</tr>
<tr>
<td>Bisphosphonates</td>
<td></td>
<td>↓ number of MDSCs inside tumor stroma</td>
<td>M</td>
<td>Ugel et al</td>
</tr>
<tr>
<td>Triterpenoids</td>
<td></td>
<td>↓ IF of MDSCs</td>
<td>F</td>
<td>Apetoh et al</td>
</tr>
<tr>
<td>Phosphodiesterase-5 inhibitors</td>
<td>Head and neck cancer, myeloma</td>
<td>↓ arginine and NOS expression</td>
<td>F</td>
<td>Apetoh et al, Ugel et al, Nagaraj and Gabrilovich</td>
</tr>
<tr>
<td>COX2 inhibitors</td>
<td></td>
<td>Downregulation of arginine and NOS expression of MDSCs</td>
<td>F</td>
<td>Ugel et al</td>
</tr>
<tr>
<td>Docetaxel</td>
<td></td>
<td>Polarization of MDSCs toward M1</td>
<td>F</td>
<td>Apetoh et al</td>
</tr>
<tr>
<td>Bindarit</td>
<td></td>
<td>↓ CCL2 production, → ↓ recruitment of MDSCs</td>
<td>A</td>
<td>Sevko and Umansky</td>
</tr>
<tr>
<td>S-FU</td>
<td></td>
<td>↑ depletion of MDSCs, ↑  cell death through inhibition of thymidylate synthase</td>
<td>A</td>
<td>Apetoh et al, Ugel et al</td>
</tr>
<tr>
<td>Gemcitabine</td>
<td>Pancreatic</td>
<td>↓ number of MDSCs, ↑ (elimination and apoptosis) direct cytotoxicity</td>
<td>A</td>
<td>Martin et al, Apetoh et al</td>
</tr>
<tr>
<td>Ipilimumab (CTLA-4)</td>
<td>Melanoma, prostate</td>
<td>↓ number of Tregs, ↓ IF of Tregs</td>
<td></td>
<td>Graziani et al, Singh et al, Hodi et al</td>
</tr>
<tr>
<td>Tremelimumab</td>
<td>Melanoma</td>
<td>↓ number of Tregs</td>
<td></td>
<td>Reuben et al</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>Melanoma</td>
<td>↓ number of Tregs, ↓ IF of Tregs</td>
<td></td>
<td>Tongu et al, Zou</td>
</tr>
<tr>
<td>COX2 inhibitors</td>
<td>Breast, lung</td>
<td>↓ IF, ↓ recruitment of Tregs, ↓ number of Tregs through inhibition of protein synthesis and ↑ apoptosis</td>
<td></td>
<td>Karavitis et al, Sharma et al</td>
</tr>
<tr>
<td>Denileukin diftitox</td>
<td>Melanoma, renal cell</td>
<td>↓ function of Tregs</td>
<td></td>
<td>Pere et al</td>
</tr>
<tr>
<td>PD-1</td>
<td>Metastatic breast</td>
<td>↓ of circulating Tregs</td>
<td></td>
<td>Zitovgel and Kroemer, Ménetrier-Caux et al, Topalian et al</td>
</tr>
<tr>
<td>Daclizumab/basiliximab (anti-CD25 mAbs)</td>
<td>Metastatic breast</td>
<td></td>
<td></td>
<td>Ménetrier-Caux et al</td>
</tr>
</tbody>
</table>

Notes: *PD-1 is better tolerated than CTLA-4; **clinically ineffective.

Abbreviations: 5-FU, fluorouracil; A, accumulation; ATRA, all-trans retinoic acid; CCL2, chemokine (C-C motif) ligand 2; CD, cluster of differentiation; COX2, cyclooxygenase-2; CTLA-4, cytotoxic T-lymphocyte antigen 4; D, differentiation; F, function; IF, immunosuppressive function; M, maturation; M1, type 1 macrophage; mAbs, monoclonal antibodies; NOS, nitric oxide synthase; PD-1, programmed cell death protein 1; PMA, principal mechanism of action; ROS, reactive oxygen species; STAT3, signal transducer and activator of transcription 3; VEGF, vascular endothelial growth factor.

metronomic cyclophosphamide, denileukin diftitox, (2) by irradiation, (3) by inhibition of Treg function (CTLA-4 antibodies [ie, ipilimumab]), (4) by blocking their migration to the tumor, and (5) by modifying key molecules in tumor microenvironment (ie, COX2 inhibitors, STAT3, extracellular cyclic AMP and adenosine) (Table 1 and Figure 1).

A molecule of special interest for controlling Treg is ipilimumab, Ipilimumab (Yervoy, Bristol-Myers Squibb, New York, NY, USA) is a human immunoglobulin 1 monoclonal antibody able to bind to CTLA-4 receptors, thus blocking their interaction with protein B7. Several clinical trials have been conducted with this drug, particularly on melanoma and castration-resistant prostate cancer. A survival benefit has been obtained using a dose of 3 mg/kg endovenous every 3 weeks for four doses, with or without a melanoma vaccine polypeptide (glycoprotein 100).

An ipilimumab study by Hodi et al showed a median overall improvement in survival for stage III and IV melanoma patients from 6 to 10 months, and the drug's efficacy was unaffected by the presence of glycoprotein 100 vaccine.
previously untreated metastatic melanoma, demonstrated an improvement in survival time, but increased side effects when compared with dacarbazine alone.\textsuperscript{107} Melanoma patients with brain metastases\textsuperscript{108} as well as cases of uveal melanoma\textsuperscript{109} have improved survival with Yervoy. Ipilimumab use has also been suggested for castration-resistant prostate cancer,\textsuperscript{109} but increased side effects when compared with dacarbazine alone.

It has been suggested that monoclonal antibodies (mAbs) do not easily reach the targeted tumor mass.\textsuperscript{112} Reuben et al used another CTLA-4 inhibitor, ticilimumab (now called “tremelimumab”), in melanoma, and achieved results similar to those obtained with ipilimumab.\textsuperscript{113}

Another class of immune checkpoint protein blockers is aimed to act as mAbs to programmed death receptor-1 (PD-1)\textsuperscript{114} and its ligand, PD-L1. These receptors are not only expressed on MDSC cells and T<sub>reg</sub> but are also overexpressed in a variety of human cancers including lung, ovarian, skin, colon, esophagus, renal, stomach, and breast.\textsuperscript{115,116} Another humanized mAb, BMS-936558 (immunoglobulin 4; Bristol-Myers Squibb), has generated interesting, albeit preliminary, results.\textsuperscript{117} The most striking of these is that melanoma and renal-cell cancers are the most responsive tumors — second only to those which immunohistochemical analysis shows are...
positive for PD-1 receptors on their surface.\textsuperscript{119–121} Side effects have been less severe than with Yervoy according to Tang and Heng,\textsuperscript{121} who assert that PD-L1 is selectively expressed on many tumors and within the tumor microenvironment when compared with CTLA-4. The most common side effects reported with use of the anti-PD-L1 antibody BMS-936559 and anti-PD-1 antibodies (eg, BMS-936558) have been fatigue, rash, pruritus, arthralgia, and nausea (listed in order of appearance).\textsuperscript{121} As some authors have outlined, a combination of PD-1 and CTLA-4 antibodies seems possible and may be potentially synergistic; however, some caution must be exercised when using this combination in humans.\textsuperscript{122}

The last group of immunosuppressive molecules released by tumors that we address here is exosomes. Exosomes are microparticles 30–100 $\mu$m in size containing a variety of different molecules from signal peptides to mRNA, micro RNA, and lipids. They are either released into the extracellular fluid or may enter circulation, resulting in an increase in T effector cells,\textsuperscript{122} tumor progression,\textsuperscript{124} and tumor immune evasion.\textsuperscript{122} Recently, an interesting approach to removing these particles has been used that merits some attention. Using an ADAPT\textsuperscript{TM} device (a “Hemopurifier”\textsuperscript{19} by Aethlon Medical, San Diego, CA, USA), Marleau et al\textsuperscript{19} were able to remove exosomes containing human epidermal growth factor receptor 2 oncoproteins in patients with breast cancer overexpressing human epidermal growth factor receptor 2 receptors. This method is not altogether new, but the first attempts by Lentz\textsuperscript{126} used ultrapheresis in the treatment of solid tumors. This newer Hemopurifier approach uses the same cartridges used in standard dialysis units, thus does not require the purchase of a new device, making this a novel and easily incorporated technique.

**Conclusion**

Cancer is a complex system that learns to adapt to its environment, slowly recruiting its host for its own selfish growth and maintenance needs and to evade the immune system. Our rapidly developing understanding of the immune system and the tumor microenvironment is allowing researchers and clinicians to better target treatments against cancer. Understanding that the tumor microenvironment is hypoxic and in a state of chronic inflammation allows us to change variables to make the stroma less tumor promoting. Stimulation of the innate immune system may lead to short-term benefits, to have a long-term benefit it must be followed by DC, IL-2/LAK or similar cytotoxic cell infusion. There are many exciting mAbs and drugs developed against various immune-related receptors such as Ipilimumab or PD-1, and for controlling T effector cells and MDSCs. Such immune system treatments hold a lot of promise. By harnessing our understanding of the immune system, we will be better able to work with this incredible system. By combining treatments aimed at both immunity and tumor microenvironment, it is our belief that a new benchmark in metastatic cancer therapy will be achieved.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


